Detalhe da pesquisa
1.
The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Int J Mol Sci
; 24(24)2023 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38139260
2.
A prodrug design for improved oral absorption and reduced hepatic interaction.
Bioorg Med Chem
; 25(20): 5569-5575, 2017 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28886996
3.
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
NPJ Precis Oncol
; 8(1): 118, 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38789520
4.
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.
Biochim Biophys Acta Rev Cancer
; 1877(4): 188737, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680099
5.
Targeting LIF/LIFR signaling in cancer.
Genes Dis
; 9(4): 973-980, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35685476
6.
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
Cancers (Basel)
; 14(21)2022 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36358818
7.
Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
J Nanosci Nanotechnol
; 11(5): 3789-99, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21780370
8.
Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer.
Pharmaceuticals (Basel)
; 14(12)2021 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34959717
9.
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Cell Death Discov
; 7(1): 216, 2021 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34400617
10.
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Commun Biol
; 4(1): 1235, 2021 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716410
11.
BU-32: a novel proteasome inhibitor for breast cancer.
Breast Cancer Res
; 11(5): R74, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19821999
12.
Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta.
Mol Hum Reprod
; 15(10): 665-73, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19505996
13.
Elevated aromatase expression correlates with cervical carcinoma progression.
Gynecol Oncol
; 114(3): 496-500, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19555998
14.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Mol Endocrinol
; 22(3): 649-64, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18079323
15.
Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression.
Cancer Res
; 67(5): 1918-26, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17332318
16.
Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.
Biomed Rep
; 11(5): 222-229, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31632670
17.
Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer.
Oncol Lett
; 17(6): 5261-5266, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186742
18.
EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Sci Rep
; 9(1): 17279, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31754172
19.
Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma.
Genes Cancer
; 10(1-2): 1-10, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30899415
20.
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Mol Cancer Ther
; 18(8): 1341-1354, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142661